BCAX - Bicara Therapeutics Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.33
DETAILS
HIGH:
$42.00
LOW:
$18.00
MEDIAN:
$37.00
CONSENSUS:
$32.33
UPSIDE:
15.63%
About Bicara Therapeutics Inc. Common Stock (https://www.bicara.com)
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Claire Mazumdar Clemon | Chief Executive Officer & Director | 1990 | $927,688 USD |
| Ivan Hyep | CFO & Treasurer | 1985 | $915,375 USD |
| Ryan Cohlhepp | President, Chief Operating Officer & Director | 1977 | $858,400 USD |
| Angela Windt | Vice President & Head of Regulatory Affairs | – | – |
| Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance | – | – |
| Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | – | – |
| Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary | 1972 | – |
| Pauline Dufresne | Chief People Officer | – | – |
| Rachel Frank | Vice President of Investor Relations and Corporate Communications | – | – |
| Rachel Salazar | SVP of R&D Strategy and Operations | – | – |
| Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | – | – |